RU1808325C - Method of articular syndrome treatment in rheumatic arthritis - Google Patents

Abstract

The invention relates to medicine, namely to rheumatology and can be used to treat articular syndrome in rheumatoid arthritis. An object of the invention is to prevent relapse of the disease. The goal is achieved by introducing cerucal into the affected joint at a dose of 2-10 mg 2-3 times with an interval of 7-8 days. The method allows to prevent the recurrence of rheumatoid arthritis and the progression of destructive changes in the joints, does not give complications. 1 tab.

Description

The invention relates to medicine, namely to rheumatology.

A known method of treating articular syndrome in rheumatoid arthritis by intra-articular injections of corticosteroids ... . .

The purpose of the invention is the prevention of relapse of the disease.

This goal is achieved in that a solution of cerucal in a dose of 2-10 mg 2t3 times with an interval of 7-8 days is injected into the patient's joint.

The use of cerucal as an antiemetic agent for diseases of the gastrointestinal tract and for various intoxications is known. Cerucal is widely used in gastroenterology to stimulate the activity of the stomach and small intestine. We first discovered the anti-inflammatory and analgesic properties of cerucal. A prerequisite for the use of cerucal in rheumatoid arthritis was the inhibitory synthesis of srmatotropin by the action of cerucal through blockade of dopamine receptors. It has been found that high levels of somatrtropin with rheumatoid arthritis

stimulate autoimmune inflammatory process and contribute to the development of severe destructive changes in the affected joints.

A method for treating articular syndrome in rheumatoid arthritis is as follows.

In addition to the strict conditions of asepsis and antiseptics, a solution of cerucal is introduced into the affected joint at a dose of 2-10 mg, depending on the volume of the joint. 2-3 injections with an interval of 7-8 days are prescribed for the course of treatment, -.

The clinical efficacy of treating articular syndrome with cerucal for rheumatoid arthritis is evaluated by the following indicators: pain index (assessment of the severity of joint pain in patients using a 4-point system); swelling index (numerical expression of swelling, estimated visually by a 4-point system); joint circumference in mm; range of motion in the joint in degrees.

As a rule, from the second day the signs of arthritis decreased and the general condition of the patients improved (see table).

(L

WITH

with

about

00

00

y eat

Intraarticular therapy with cerucal contributed to both a reduction in the signs of arthritis and a decrease in somatotropin levels.

PRI me R 1. Patient L. was admitted to the hospital with a diagnosis of Rheumatoid arthritis, articular form, stage III, active 111 degree, slowly progressing course, NSF III, Sick for 12 years, complaints of joint pain, restriction movements, stiffness before noon, general weakness. An objective examination determines the swelling in the knee joints, limitation of movements in them to 110 ° hyperthermia of the joints, hypotrophy and muscle tension of the lower extremities. In the lungs, vesicular breathing, cardiac sounds are muffled, moderate tachycardia, pulse 90 in 1 min. The abdomen is soft, painless.

Laboratory data: general blood test: red blood cells 3.5 million: color indicator 0.8; hemoglobin 78 g / l; white blood cells 5.6 thousand, ESR 45 mm / h. Biochemical analysis of blood: C-reactive protein 3 (+); RF 2 (+); total protein 72 g / l; albumin 36%; globulins 54%; glucose 4.4 mm / l; thymol sample 0.467; definylamine 320 units. Somatotropin blood 5.6 ng / ml, synovial fluid 7.8 ng / ml. The patient was injected with 10 mg of cerucal into the knee joints. On the 2nd day, the patient's condition improved: the swelling in the knee joints decreased, the range of movements increased to 165 °. Cerucal was reintroduced into the knee joints after 7 days. Significant improvement in the patient’s condition was noted: she began to walk on her own, the range of motion in the knee joints was restored, the pain decreased,

and

10

fifteen

twenty

25

thirty

35

muscle tension of the lower extremities, somatotropin synovial fluid 2.7 ng / ml, blood 3.1 ng / ml disappeared. To fix the effect, a third injection of cerucal was given after 7 days.

Analyzes at discharge: ESR 7 mm / h; hemoglobin 128 g / l; red blood cells 4.3 million; white blood cells 6.1 thousand. Blood somatotropin 2.1 ng / ml; C-reactive protein is negative .; RF

1 (+) ..

A method of treating articular syndrome in rheumatoid arthritis by intra-articular injections of cerucal helps to improve the manifestations of the articular syndrome: reducing pain in the joints, the disappearance of swelling in the joints, restoration of range of motion in the joints and stress relief of the muscles of the extremities. In addition, after intraarticular administration of cerucal, a decrease in the activity of the rheumatoid process is observed, which is accompanied by a decrease in the level of somatotropin in both blood serum and synovial fluid. Intra-articular administration of cerucal in rheumatoid arthritis prevents the development of severe destructive changes in the joints, allows to shorten the treatment time, and reduce disability.

Claims (1)

SUMMARY OF THE INVENTION A method for treating articular syndrome in rheumatoid arthritis, comprising intra-articular administration of drugs, characterized in that, in order to prevent relapse of the disease, cerucal is administered in a dose of 2-10 mg 2-3 times with an interval of 7-8 days. . . . The dynamics of the articular syndrome in rheumatoid arthritis before and after intraarticular therapy with cerucal / M ± t /.